Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q2 FY23 Earnings Presentation
23 slides from Jubilant Pharmova's earnings presentation, Oct 21, 2022
Slide 1: Financial Results Quarter Ended September 30, 2022
Financial Results Quarter Ended September 30, 2022
Slide 2: Conference Call Details
Conference Call Details Date : Oct 21, 2022 Time : 05:00 pm IST +91 22 6280 1141 Primary Number +91 22 7115 8042 USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay: Oct 21 to Oct 28, 2022 Dial-in: +91 22 7194 5757 / +91 22 6663 5757 Playback
Slide 3: Chairmen's Message
Chairmen’s Message Jubilant Pharmova Q2 & H1 FY23 Key Financial Parameters Particulars1 Q2'FY22 Q1'FY23 Q2'FY23 H1'FY22 H1'FY23 Total Revenue from Operations 1,657 1,452 1,600 3,292 3,051 Reported EBITDA 344 204 232 723 436 Reported EBITDA margin (%) 20.7% 14.0% 14.5% 22.0% 14.3% Profit After Tax 14
Slide 4: Q2'FY23 Results Analysis
4 IBILANT Spence Q2'FY23 Results Analysis
Slide 5: Financial Highlights – Q2'FY23
Financial Highlights – Q2'FY23 Particulars1 Q2'FY22 Q1'FY23 Q2'FY23 Revenues were at Rs 1,600 Crore vs. Rs 1,657 Crore in Q2'FY22 and Rs 1,452 Total Revenue from Operations 1,657 1,452 1,600 Crore in Q1’FY23. Reported EBITDA 344 204 232 Depreciation and Amortisation 100 95 94 The higher volumes
Slide 6: Specialty Pharmaceuticals Segment Highlights – Q2'FY23
Specialty Pharmaceuticals Segment Highlights – Q2'FY23 Particulars1 Q2'FY22 Q1'FY23 Q2'FY23 YoY (%) Revenues were at Rs 814 Crore vs. Rs 651 Crore in Q2'FY22 and Total Revenue 651 722 814 25% Rs 722 Crore in Q1’FY23. a) Radiopharma 529 592 658 24% i) Radiopharmaceuticals 210 196 248 18% EBITDA w
Slide 7: CDMO Sterile Injectables Segment Highlights – Q2'FY23
CDMO Sterile Injectables Segment Highlights – Q2'FY23 Particulars1 Q2'FY22 Q1'FY23 Q2'FY23 YoY (%) CDMO Sterile Injectables’ revenues were at Rs 299 Crore vs. Rs 409 Revenue 409 263 299 (27%) Crore in Q2'FY22 and Rs 263 Crore in Q1’FY23 EBITDA 203 132 71 (65%) Reported EBITDA Margin (%) 49.5% 50.2
Slide 8: Generics Segment Highlights – Q2'FY23
Generics Segment Highlights – Q2'FY23 Particulars1 Q2'FY22 Q1'FY23 Q2'FY23 YoY (%) Generics revenues were at Rs 161 Crore vs. Rs 333 Crore in Q2'FY22 and Rs Revenue 333 178 161 (51%) 178 Crore in Q1’FY23. Reported EBITDA (42) (74) (82) Reported EBITDA was at Rs (82) Crore vs. Rs (42) Crore in Q2
Slide 9: CRDMO Segment Highlights – Q2'FY23
CRDMO Segment Highlights – Q2'FY23 Particulars1 Q2'FY22 Q1'FY23 Q2'FY23 YoY (%) CRDMO Total Revenue 258 280 320 24% a) Drug Discovery Services 108 118 150 39% Revenues were at Rs 320 Crore vs. Rs 258 Crore in Q2'FY22 and b) CDMO - API 150 162 170 13% Rs 280 Crore in Q1’FY23 Reported EBITDA 69 46
Slide 10: Jubilant Therapeutics: Clinical stage precision therapeutics company
Jubilant Therapeutics: Clinical stage precision therapeutics company addressing significant unmet medical needs in oncology and autoimmune diseases 99
Slide 11: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases Multiple difficult-to-target precision therapeutics oncology programs in discovery stage 1Jubilant Therapeutics out licensed its EGFR program to Lengo Therapeutics (Frazier Healthcare entity) Blueprint Medicines acquir
Slide 12: H1'FY23 Results Analysis
H1'FY23 Results Analysis 11 11
Slide 13: H1'FY23 Financial Highlights
H1'FY23 Financial Highlights Particulars1 H1'FY22 H1'FY23 Revenues were Rs 3,051 Crore versus Rs 3,292 Crore in H1'FY22. Total Revenue from Operations 3,292 3,051 Reported EBITDA at Rs 436 Crore vs. Rs 723 Crore in H1'FY22. Reported EBITDA 723 436 Depreciation and Amortisation 188 189 In H1’FY
Slide 14: Specialty Pharmaceuticals Segment Highlights – H1'FY23
Specialty Pharmaceuticals Segment Highlights – H1'FY23 Particulars1 H1'FY22 H1'FY23 YoY (%) Revenues were Rs 1,536 Crore vs. Rs 1,282 Crore in H1'FY22. Total Revenue 1,282 1,536 20% a) Radiopharma 1,047 1,250 19% EBITDA at Rs 316 Crore vs. Rs 205 Crore in H1’FY22 with a margin of 20.6% i) Radiop
Slide 15: CDMO Sterile Injectables Segment Highlights – H1'FY23
CDMO Sterile Injectables Segment Highlights – H1'FY23 Particulars1 H1'FY22 H1'FY23 YoY (%) • CDMO Sterile Injectables’ revenue at Rs 562 Crore vs. Rs 782 Crore Revenue 782 562 (28%) in H1'FY22. EBITDA 418 203 (51%) Reported EBITDA Margin (%) 53.5% 36.2% • Revenue and profitability lower vs. H1’FY22
Slide 16: Generics Segment Highlights – H1'FY23
Generics Segment Highlights – H1'FY23 Particulars1 H1'FY22 H1'FY23 YoY (%) Generics revenue at Rs 340 Crore vs. Rs 765 Crore in H1'FY22. Revenue 765 340 (56%) Reported EBITDA 11 (155) Reported EBITDA was at Rs (155) Crore vs. Rs 11 Crore in H1’FY23 Reported EBITDA Margin 1.4% (45.7%) Revenues
Slide 17: CRDMO Segment Highlights – H1'FY23
CRDMO Segment Highlights – H1'FY23 Particulars1 H1'FY22 H1'FY23 YoY (%) Revenue at Rs 600 Crore vs. Rs 451 Crore in H1'FY22 Total Revenue 451 600 33% a) Drug Discovery Services 196 268 37% EBITDA at Rs 114 Crore vs. Rs 122 Crore in H1’FY22 with a margin of b) CDMO - API 256 332 30% 19.0% vs. 27.
Slide 18: Debt Profile
Debt Profile Particulars 31-03-2022 30-06-2022 30-09-2022 Gross Debt Rs Crs Rs Crs Rs Crs Long term 2,874 2,986 3,068 Short term 64 109 186 Total 2,938 3,095 3,254 Cash & Equivalent 984 1,027 846 Net Debt (on a constant Currency 1,954 1,951 2,204 basis Net Debt (constant currency) at Rs 2,204 Cror
Slide 19: Key Business Priorities
Key Business Priorities Radiopharmaceuticals Continued ramping up of Ruby-Fill installations New Product Development and Filings (atleast 2 New Products in FY-24) Radiopharma Timely execution of MIBG roadmap to enable FY-25 launch Radiopharmacies Focus on launch of new products to gain signi
Slide 20: Business outlook
Business outlook Speciality Pharmceuticals: In radiopharma, we continue to build a long term pipeline of diagnostic and therapeutic radiopharmaceuticals and are executing a turnaround plan of radiopharmacies, which is showing encouraging results. I131 MIBG clinical trials underway with launch expe
Slide 21: Appendix
a Es ¥ oa (o) VA A p pend IX 20
Slide 22: Income Statement – Q2 & H1'FY23
Income Statement – Q2 & H1’FY23 Particulars1 Q2'FY22 Q2'FY23 YoY (%) H1'FY22 H2'FY23 YoY (%) Revenue from Operations Specialty Pharmaceuticals 651 814 25% 1,282 1,536 20% CDMO Sterile Injectables 409 299 (27%) 782 562 (28%) Generics 333 161 (51%) 765 340 (56%) Contract Research Development and Manuf
Slide 23: For more information
For more information For Investors: Surajit Pal Siddharth Rangnekar Ph: +91 120 436 1002 CDR India E-mail: Surajit.pal1@jubl.com Ph: +91 +91 9769919966 E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1062 Madison Public Relations E-mail: sudhakar.safaya@jubl